Tonix Pharmaceuticals has showcased promising preclinical data for its single-dose mpox vaccine candidate TNX-801, revealing potential breakthrough protection against mpox and rabbitpox. The oral presentation at the World Vaccine Congress Washington 2025 highlighted the vaccine's ability to provide durable protection for immunocompromised and standard animal subjects for up to six months.
The vaccine's development represents a critical response to global health emergencies, aligning with World Health Organization recommendations for mpox prevention. TNX-801's minimally replicative live-virus approach offers a potentially versatile solution for current and future mpox outbreak scenarios.
The research demonstrates significant implications for public health, particularly for vulnerable populations. By developing a single-dose vaccine that can protect immunocompromised subjects, Tonix is addressing a critical gap in infectious disease prevention strategies.
The vaccine candidate's ability to provide extended protection over six months suggests potential advantages over existing mpox prevention methods. This could represent a substantial advancement in managing and potentially controlling mpox transmission, especially in regions experiencing recurring outbreaks.
Tonix's commitment to developing innovative solutions for public health challenges is underscored by this research. The company's ongoing work in infectious disease prevention, including its state-of-the-art research facility in Maryland, positions it as a potentially significant contributor to global health security.
